IBERIABANK Corp (IBKC) Jumps 8.11% on January 28

Equities Staff |

IBERIABANK Corp (IBKC) was among the biggest gainers on the Russell 2000 for Thursday January 28 as the stock popped 8.11% to $48.41, representing a gain of $3.6313 per share. Some 364,393 shares traded hands on 3,963 trades, compared with an average daily volume of 263,837 shares out of a total float of 41.13 million. The stock opened at $47.80 and traded with an intraday range of $49.69 to $46.31.

After today's gains, IBERIABANK Corp reached a market cap of $1.99 billion. IBERIABANK Corp has had a trading range between $71.21 and $42.20 over the last year, and it had a 50-day SMA of $54.97 and a 200-day SMA of $60.81.

The stock has a P/E Ratio of 12.8.

Iberiabank Corp operates as a holding company for IBERIABANK. It offers commercial banking, private banking, mortgage lending, small business and retail banking, wealth management and investment services.

IBERIABANK Corp is based out of Lafayette, LA and has some 3,214 employees. Its CEO is Daryl G. Byrd.

For a complete fundamental analysis analysis of IBERIABANK Corp, check out Equities.com’s Stock Valuation Analysis report for IBKC. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


Pinterest is a visual discovery and planning tool. Users ("Pinners") use the site and apps to get ideas for their future, such as recipes, places to travel, and products to…

Initial State

Initial State is an Internet of Things (IoT) data analytics & data management platform company. We turn sensor and event data into information that matters by making it easy to…